Missak Haigentz

Employment

• Rutgers Cancer Institute of New Jersey Professor of Medicine and Chief, Thoracic and Head & Neck Medical Oncology
  2021 - Present
• Morristown Medical Center Section Chief
  2017 - 2021
• Albert Einstein College of Medicine, Yeshiva University Professor
  2015 - Present
• Montefiore Hospital and Medical Center Attending Physician
  2001 - 2017

Education

• NYU Langone Medical Center Fellowship
  1998 - 2001
• New Jersey Medical School Department of Medicine Residency
  1995 - 1998
• Rutgers New Jersey Medical School MD
  1991 - 1995
• University of California Los Angeles BS/Biology
  1986 - 1991

Projects & Funding

Projects & funding information is unavailable.

Publications (132)

• Data from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9
  2026 DOI: 10.1158/1078-0432.c.8653770
  +Save
• Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9
  Clinical Cancer Research 2026 DOI: 10.1158/1078-0432.CCR-25-4650
  +Save
• Figure 1 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9
  2026 DOI: 10.1158/1078-0432.33253008
  +Save
• Figure 2 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9
  2026 DOI: 10.1158/1078-0432.33253005
  +Save
• Supplementary Data 1 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9
  2026 DOI: 10.1158/1078-0432.33253002
  +Save
• Table 1 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9
  2026 DOI: 10.1158/1078-0432.33252999
  +Save
• Table 2 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9
  2026 DOI: 10.1158/1078-0432.33252996
  +Save
• Table 3 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9
  2026 DOI: 10.1158/1078-0432.33252993
  +Save
• Table 4 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9
  2026 DOI: 10.1158/1078-0432.33252990
  +Save
• Data from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
  2025 DOI: 10.1158/1078-0432.c.6790375
  +Save